Cargando…

Stem cell therapy for Parkinson's disease

Transplantation of human fetal dopamine (DA) neurons to patients with Parkinson's disease (PD) has given proof of the principle that new neurons can survive for at least a decade, and then functionally integrate and provide significant symptomatic relief. Unfortunately, the ethical, technical,...

Descripción completa

Detalles Bibliográficos
Autor principal: Björklund, Lars M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Les Laboratoires Servier 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181808/
https://www.ncbi.nlm.nih.gov/pubmed/22033634
_version_ 1782212817003216896
author Björklund, Lars M.
author_facet Björklund, Lars M.
author_sort Björklund, Lars M.
collection PubMed
description Transplantation of human fetal dopamine (DA) neurons to patients with Parkinson's disease (PD) has given proof of the principle that new neurons can survive for at least a decade, and then functionally integrate and provide significant symptomatic relief. Unfortunately, the ethical, technical, and practical limitations of using fetal DA neurons as the source for cell transplantation in PD, in combination with the development of unwanted grafting-related side effects, have put a halt to the spread of this treatment into clinical practice. Hopefully, recent advances in the fields of stem cell biology and adult neurogenesis research will lead totamen in new exciting ways to better understand and control the biological parameters necessary for achieving safe and successful neuronal replacement in PD patients.
format Online
Article
Text
id pubmed-3181808
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher Les Laboratoires Servier
record_format MEDLINE/PubMed
spelling pubmed-31818082011-10-27 Stem cell therapy for Parkinson's disease Björklund, Lars M. Dialogues Clin Neurosci Basic Research Transplantation of human fetal dopamine (DA) neurons to patients with Parkinson's disease (PD) has given proof of the principle that new neurons can survive for at least a decade, and then functionally integrate and provide significant symptomatic relief. Unfortunately, the ethical, technical, and practical limitations of using fetal DA neurons as the source for cell transplantation in PD, in combination with the development of unwanted grafting-related side effects, have put a halt to the spread of this treatment into clinical practice. Hopefully, recent advances in the fields of stem cell biology and adult neurogenesis research will lead totamen in new exciting ways to better understand and control the biological parameters necessary for achieving safe and successful neuronal replacement in PD patients. Les Laboratoires Servier 2004-09 /pmc/articles/PMC3181808/ /pubmed/22033634 Text en Copyright: © 2004 LLS http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Basic Research
Björklund, Lars M.
Stem cell therapy for Parkinson's disease
title Stem cell therapy for Parkinson's disease
title_full Stem cell therapy for Parkinson's disease
title_fullStr Stem cell therapy for Parkinson's disease
title_full_unstemmed Stem cell therapy for Parkinson's disease
title_short Stem cell therapy for Parkinson's disease
title_sort stem cell therapy for parkinson's disease
topic Basic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181808/
https://www.ncbi.nlm.nih.gov/pubmed/22033634
work_keys_str_mv AT bjorklundlarsm stemcelltherapyforparkinsonsdisease